AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-83 (Canceled).

84. (New) A compound having the formula (I), or a pharmaceutically acceptable derivative, salt, racemate, isomer or tautomer thereof:

wherein

Z is S or CH₂;

 R_1 is a linking moiety;

M is a zinc binding moiety containing at least one heteroatom;

R₆ is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl and a nitrogen protecting group;

X is selected from the group consisting of:

National Stage of PCT/AU2004/001667 Attorney Docket No. P1119/20002 Preliminary Amendment Dated: May 26, 2006

-CH₂— ,
$$\overset{O}{\overset{\parallel}{\parallel}}$$
 , $\overset{S}{\overset{\parallel}{\parallel}}$, and $\overset{O}{\overset{\parallel}{\parallel}}$;

Y is selected from the group consisting: of -NR₄R₅, -OR₄, -SR₄, -CH₂R₄, CHR₄R₅, $C(R_4)_2R_5$, PHR₄ and PR₄R₅,

wherein R₄ is a group of formula:

$$\{ (R_8)_p - (R_9)_q + \begin{pmatrix} O & H \\ || & | \\ C - N \end{pmatrix}_T - (R_{10})_s$$

wherein R₈, R₉ and R₁₀ are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl;

p, q, r and s are each independently 0 or 1, provided that at least one of p, q or s is 1;

R₅ is H or a group of formula:

$$\begin{cases} (R_{11})_t - (R_{12})_u + \begin{pmatrix} O & H \\ || & | \\ C - N \end{pmatrix}_v (R_{13})_w$$

wherein R₁₁, R₁₂ and R₁₁₃ are each independently selected from the group consisting of

optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl;

t, u, v and w are each independently 0 or 1, provided that at least one of t, u and w is 1;

R₇ is a group of formula:

$$(R_{16})_z$$
- $(R_{15})_y$ - $(R_{14})_x$ -

wherein R₁₄, R₁₅ and R₁₆ are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl,

x, y and z are independently 0 and 1 with the proviso that at least one of x, y and z is 1, with the proviso that:

when Z is CH₂ and Y is
$$-\mathbb{N}$$
, $-\mathbb{N}$, $-\mathbb{N}$, or $-\mathbb{N}$, then R₆ is not H, X is not $-\mathbb{C}$ and R₇ is not $-\mathbb{N}$, $-$

when Z is
$$CH_2$$
 and Y is $\stackrel{-N}{\longrightarrow}$, then R_6 is not H, X is not $\stackrel{\circ}{-c}$ and R_7 is not $-CH_3$.

85. (New) A compound as in claim 84, wherein the zinc binding moiety is a group of formula $-C(O)-NR_2-OR_3$ where R_2 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or a nitrogen protecting group and R_3 is H, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted aryl or an oxygen protecting group.

86. (New) A compound as in claim 85, wherein the linking moiety has between 1 and 9 atoms in the normal chain.

87. (New) A compound as in claim 86, wherein the linking moiety is an n-propyl chain.

88. (New) A compound having the formula (IIIa), or a pharmaceutically acceptable derivative, salt, racemate, isomer or tautomer thereof:

$$R_7$$
 X
 N
 R_5
 R_4
 R_1
 $C(O)$
 R_2

(IIIa)

wherein

R₁ is optionally substituted C₁-C₄ alkyl, optionally substituted C₁-C₄ alkenyl or optionally substituted C₁-C₄ alkynyl;

R₂ is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or a nitrogen protecting group;

R₃ is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or an oxygen protecting group;

R₄ is a group of formula:

$$\{ (R_8)_p - (R_9)_q - \begin{pmatrix} O & H \\ II & I \\ C - N \end{pmatrix}_r - (R_{10})_s$$

wherein R₈, R₉ and R₁₀ are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl;

p, q, r and s are each independently 0 or 1, provided that at least one of p, q or s is 1;

 R_5 is H or a group of formula:

$$\begin{cases} (R_{11})_t - (R_{12})_u + \begin{pmatrix} O & H \\ || & | \\ C - N \end{pmatrix}_V (R_{13})_w \end{cases}$$

wherein R₁₁, R₁₂ and R₁₁₃ are each independently selected from the group consisting of

optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl;

t, u, v and w are each independently 0 or 1, provided that at least one of t, u and w is 1.

R₆ is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl and a nitrogen protecting group;

X is selected from the group consisting of

—CH₂— ,
$$\overset{O}{=}$$
 , $\overset{S}{=}$, and $\overset{O}{=}$,

 R_7 is a group of formula:

$$(R_{16})_z$$
- $(R_{15})_v$ - $(R_{14})_x$ -

wherein R₁₄, R₁₅ and R₁₆ are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted heterocycloalkyl;

x, y and z are independently 0 and 1 with the proviso that at least one of x, y and z is 1.

- 89. (New) A compound as in claim 88, wherein R_1 is n-propyl.
- 90. (New) A compound as in claim 88, wherein R_2 is either H, optionally substituted C_1 - C_4 alkyl or a nitrogen protecting group.
- 91. (New) A compound as in claim 88, wherein R₃ is either H, optionally substituted C₁-C₄ alkyl or an oxygen protecting group.
 - 92. (New) A compound as in claim 88, wherein R₄ is of the formula:

$$\begin{array}{c|c}
 & H \\
 & | & | \\
 & -R_8-R_9-C-N-R_{10}
\end{array}$$

wherein R₈, R₉ and R₁₀ are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl.

93. (New) A compound as in claim 92, wherein R₄ is a group of the formula.

$$-CH_2 \longrightarrow \begin{array}{c} (R)_n & O & H \\ & || & | \\ C-N & \\ \end{array}$$

wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloalkenyl, haloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy,

haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkynylacyl, arylacyl, heteroarylacyl, acylamino, diacylamino, acyloxy, alkylsulphonyloxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphonyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate;

n is 0-4, and

m is 0-5.

94. (New) A compound as in claim 92, wherein R₄ has one of the following formulae:

wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloalkeroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino,

alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl, heteroarylacyl, acylamino, diacylamino, acyloxy, alkylysulphonlyoxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphnyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate;

and each m is from 0-5.

- 95. (New) A compound as in claim 88, wherein R₅ is either H or optionally substituted alkyl.
 - 96. (New) A compound as in claim 88, wherein X is a carbonyl group.
- 97. (New) A compound as in claim 96, wherein R₆ is either H or a nitrogen protecting group.
- 98. (New) A compound as in claim 96, wherein R₇ is selected from the group consisting of optionally substituted alkyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted aryl alkyl, optionally substituted heterocycloalkyl alkyl, optionally substituted heterocycloalkyl alkyl, optionally substituted heterocycloalkyl alkyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted heterocycloalkyl alkynyl, optionally substituted heterocycloalkyl alkynyl, optionally substituted heterocycloalkyl alkynyl, optionally substituted heterocycloalkyl alkynyl, optionally substituted heterocycloalkyl alkynyl.
- 99. (New) A compound as in claim 88, wherein the compound has a potency of cytotoxicity of IC₅₀ \leq 10 μ M against MM96 melanoma cells.

100. (New) A compound as in claim 99, wherein the compound has a Selectivity Index of > 1.5.

101. (New) A compound as in claim 100, wherein the compound has a potency of $IC_{50} \le 1 \mu M$ against the MM96 melanoma cells and a Selectivity Index of ≥ 3 .

102. (New) A compound as in claim 101, wherein the compound has a potency of $IC_{50} \le 0.5 \mu M$ against the MM96 melanoma cells and a Selectivity Index of ≥ 4 .

103. (New) A compound as in claim 84, wherein the compound has the formula (IIIb):

(IIIb)

wherein

R₄ is a group of formula:

$$\{ (R_8)_p - (R_9)_q - \begin{pmatrix} O & H \\ || & | \\ C - N \end{pmatrix}_r - (R_{10})_s$$

wherein R₈, R₉ and R₁₀ are each independently selected from the group consisting of

optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocycloalkyl;

p, q, r and s are each independently 0 or 1, provided that at least one of p, q or s is 1;

R₅ is H or a group of formula:

$$\begin{cases} (R_{11})_t - (R_{12})_u + \begin{pmatrix} O & H \\ || & | \\ C - N \end{pmatrix}_V (R_{13})_w \end{cases}$$

wherein R₁₁, R₁₂ and R₁₁₃ are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl;

t, u, v and w are each independently 0 or 1, provided that at least one of t, u and w is 1.

R₆ is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl and a nitrogen protecting group;

X is selected from the group consisting of

-CH₂— ,
$$\begin{array}{c} O \\ \parallel \\ -C - \\ \end{array}$$
 , $\begin{array}{c} S \\ \parallel \\ -C - \\ \end{array}$, and $\begin{array}{c} O \\ \parallel \\ -S - \\ \end{array}$;

 R_7 is a group of formula:

$$(R_{16})_z$$
- $(R_{15})_y$ - $(R_{14})_x$ -

wherein R₁₄, R₁₅ and R₁₆ are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl;

x, y and z are independently 0 and 1 with the proviso that at least one of x, y and z is 1.

104. (New) A compound as in claim 103, wherein R_4 is of the formula:

$$\begin{array}{c|c}
 & H \\
 & | & | \\
 & -R_8-R_9-C-N-R_{10}
\end{array}$$

wherein R₈, R₉ and R₁₀ are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkynyl, optionally substituted alkynyl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl.

105. (New) A compound as in claim 104, wherein R₄ is a group of the formula.

$$-CH_2 \longrightarrow \begin{array}{c} (R)_n & O & H \\ & || & | \\ C-N & \\ \end{array}$$

wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, h haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl. nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkynylacyl, arylacyl, heteroarylacyl, acylamino, alkenylacyl, diacylamino, alkylsulphonyloxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphonyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate;

n is 0-4, and

m is 0-5.

106. (New) A compound as in claim 103, wherein R₄ has one of the following formulae:

$$\begin{array}{c|ccccc} (R)_{m} & (R)_{m} & (R)_{m} \\ \hline & -alkyl & -alkenyl & -alkenyl & (R)_{m} \\ \hline & -alkenyl & -alkenyl & -alkenyl & (R)_{m} \\ \hline \end{array}$$

wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl,

National Stage of PCT/AU2004/001667 Attorney Docket No. P1119/20002

Preliminary Amendment Dated: May 26, 2006

haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl, heteroarylacyl, acylamino, diacylamino, acyloxy, alklysulphonlyoxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphnyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate;

and each m is from 0-5.

107. (New) A compound as in claim 103, wherein R_5 is H.

108. (New) A compound as in claim 103, wherein X is a carbonyl group.

109. (New) A compound as in claim 108, wherein R₆ is either H or a nitrogen protecting group.

110. (New) A compound as in claim 108, wherein R₇ is selected from the group consisting of optionally substituted alkyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted aryl alkyl, optionally substituted heterocycloalkyl alkyl, optionally substituted heterocycloalkyl alkyl, optionally substituted heterocycloalkyl alkyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted heterocycloalkyl alkynyl, optionally substituted heterocycloalkyl alkynyl, optionally substituted heterocycloalkyl alkynyl, optionally substituted heterocycloalkyl alkynyl,

111. (New) A compound as in claim 103, wherein the compound has a potency of cytotoxicity of IC₅₀ \leq 10 μ M against MM96 melanoma cells.

112. (New) A compound as in claim 111, wherein the compound has a Selectivity Index of ≥ 1.5 .

113. (New) A compound as in claim 112, wherein the compound has a potency of $IC_{50} \le 1 \mu M$ against the MM96 melanoma cells and a Selectivity Index of ≥ 3 .

114. (New) A compound as in claim 113, wherein the compound has a potency of $IC_{50} \le 0.5 \,\mu\text{M}$ against the MM96 melanoma cells and a Selectivity Index of ≥ 4 .

115. (New) A method for the treatment of cancer in an animal, the method including the step of administering to the animal in need of such treatment an effective amount of a compound having the formula (I), or a pharmaceutically acceptable derivative, salt, racemate, isomer or tautomer thereof:

wherein

Z is S or -CH₂-;

 R_1 is a linking moiety;

M is a zinc binding moiety containing at least one heteroatom;

R₆ is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl and a nitrogen protecting group:

X is selected from the group consisting of:

-CH₂-- ,
$$\begin{array}{c} O \\ \parallel \\ -C- \end{array}$$
 , $\begin{array}{c} S \\ \parallel \\ -C- \end{array}$, and $\begin{array}{c} O \\ \parallel \\ -S- \end{array}$;

Y is selected from the group consisting: of -NR₄R₅, -OR₄, -SR₄, -CH₂R₄, CHR₄R₅, $C(R_4)_2R_5$, PHR₄ and PR₄R₅,

wherein R₄ is a group of formula:

$$\begin{cases} -(R_8)_p - (R_9)_q - \begin{pmatrix} O & H \\ || & | \\ C - N \end{pmatrix}_r - (R_{10})_s$$

wherein R₈, R₉ and R₁₀ are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl;

p, q, r and s are each independently 0 or 1, provided that at least one of p, q or s is 1;

R₅ is H or a group of formula:

$$= (R_{11})_t - (R_{12})_u + \begin{pmatrix} O & H \\ || & | \\ C - N \end{pmatrix}_v (R_{13})_w$$

wherein R₁₁, R₁₂ and R₁₁₃ are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl;

t, u, v and w are each independently 0 or 1, provided that at least one of t, u and w is 1;

R₇ is a group of formula:

$$(R_{16})_z$$
- $(R_{15})_y$ - $(R_{14})_x$ -

wherein R₁₄, R₁₅ and R₁₆ are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl,

x, y and z are independently 0 and 1 with the proviso that at least one of x, y and z is 1,

with the proviso that:

Preliminary Amendment Dated: May 26, 2006

when Z is CH₂ and Y is
$$-\bigcirc$$
, $-\bigcirc$, or $-\bigcirc$, then R₆ is not H, X is not $-\stackrel{\circ}{\text{C}}$ and R₇ is not $-\bigcirc$, $-$

when Z is CH_2 and Y is , then R_6 is not H, X is not $-\overset{\circ}{C}$ and R_7 is not $-CH_3$.

116. (New) A method as in claim 115, wherein the linking moiety has between 1 and 9 atoms in the normal chain.

117. (New) A method as in claim 116, wherein the linking moiety is an n-propyl chain.

118. (New) A method as in claim 115, wherein Z is S.

119. (New) A method as in claim 115, wherein the compound has the formula (III):

$$R_{7}$$
 X
 N
 R_{5}
 R_{4}
 Z
 R_{1}
 $C(O)$
 N
 R_{2}
(III)

wherein

National Stage of PCT/AU2004/001667 Attorney Docket No. P1119/20002 Preliminary Amendment Dated: May 26, 2006

Z is S or CH₂;

 R_1 is optionally substituted C_1 - C_4 alkyl, optionally substituted C_1 - C_4 alkenyl or optionally substituted C_1 - C_4 alkynyl;

R₂ is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or a nitrogen protecting group;

R₃ is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or an oxygen protecting group; R₄ is a group of formula:

$$\{ (R_8)_p - (R_9)_q + \begin{pmatrix} O & H \\ || & | \\ C - N \end{pmatrix}_T (R_{10})_s$$

wherein R₈, R₉ and R₁₀ are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl;

p, q, r and s are each independently 0 or 1, provided that at least one of p, q or s is 1;

R₅ is H or a group of formula:

$$= (R_{11})_t - (R_{12})_u + \begin{pmatrix} O & H \\ || & | \\ C - N \end{pmatrix}_V - (R_{13})_w$$

wherein R₁₁, R₁₂ and R₁₁₃ are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl;

t, u, v and w are each independently 0 or 1, provided that at least one of t, u and w is 1;

R₆ is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl and a nitrogen protecting group;

X is selected from the group consisting of

$$-CH_2-$$
 , $-C-$, $-C-$, and $-S-$;

 R_7 is a group of formula:

$$(R_{16})_z$$
- $(R_{15})_v$ - $(R_{14})_x$ -

wherein R₁₄, R₁₅ and R₁₆ are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl,

x, y and z are independently 0 and 1 with the proviso that at least one of x, y and z is 1.

- 120. (New) A method for the treatment of cancer as in claim 119, wherein R_1 is optionally substituted C_1 - C_4 alkyl.
- 121. (New) A method for the treatment of cancer as in claim 120, wherein R_1 is propyl.
 - 122. (New) A method for the treatment of cancer as in claim 119, wherein Z is S.
- 123. (New) A method for the treatment of cancer as in claim 119, wherein R_2 is either H, optionally substituted C_1 - C_4 alkyl or a nitrogen protecting group.
- 124. (New) A method for the treatment of cancer as in claim 119, wherein R_3 is either H, optionally substituted C_1 - C_4 alkyl or an oxygen protecting group.
- 125. (New) A method for the treatment of cancer as in claim 119, wherein R₄ is of the formula:

wherein R₈, R₉ and R₁₀ are each independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl.

126. (New) A method for the treatment of cancer as in claim 125, wherein R_4 is a group of the formula.

National Stage of PCT/AU2004/001667 Attorney Docket No. P1119/20002 Preliminary Amendment Dated: May 26, 2006

$$-CH_2 \longrightarrow \begin{array}{c} (R)_n & O & H \\ & || & | \\ C-N & \\ \end{array}$$

wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloaryl, haloacycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, diacylamino, acyloxy, alkynylacyl, arylacyl, heteroarylacyl, acylamino, diacylamino, acyloxy, alkylsulphonyloxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphonyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate;

n is 0-4, and

m is 0-5.

127. (New) A method for the treatment of cancer as in claim 119, wherein R₄ has one of the following formulas:

National Stage of PCT/AU2004/001667 Attorney Docket No. P1119/20002 Preliminary Amendment Dated: May 26, 2006

Wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkynyl, haloaryl, haloheteroaryl, halocycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy. halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl, heteroarylacyl, acylamino, diacylamino, acyloxy, alklysulphonlyoxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphnyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate:

and each m is from 0-5.

128. (New) A method for the treatment of cancer as in claim 119, wherein R_5 is either H or optionally substituted alkyl.

129. (New) A method for the treatment of cancer as in claim 119, wherein X is a carbonyl group.

130. (New) A method for the treatment of cancer as in claim 129, wherein R_6 is either H or a nitrogen protecting group.

131. (New) A method for the treatment of cancer as in claim 129, wherein R₇ is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl alkyl, optionally substituted heterocycloalkyl alkyl, optionally substituted heterocycloalkyl alkyl, optionally substituted aryl alkenyl, optionally substituted heterocycloalkyl alkyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted heterocycloalkyl alkenyl, optionally substituted heterocycloalkyl alkynyl, optionally substituted heterocycloalkyl alkynyl, optionally substituted heterocycloalkyl alkynyl, optionally substituted heterocycloalkyl alkynyl, and optionally substituted heterocycloalkyl alkynyl.

132. (New) A method for the treatment of cancer as in claim 131, wherein R₇ has one of the following formula:

$$(R)_{p}$$

$$(R)_{p}$$

$$-alkyl$$

$$(R)_{p}$$

$$(R)_{p}$$

$$(R)_{p}$$

$$(R)_{p}$$

$$-alkenyl$$

$$-alkenyl$$

wherein each R is independently selected from the group consisting of alkyl, alkenyl, alkynyl,

aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloaryl, haloacycloalkyl, haloheterocycloalkyl, hydroxy, alkoxy, alkenyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, halohetoraryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheteroaryl, nitroheterocyclyoalkyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkynylacyl, arylacyl, heteroarylacyl, acylamino, diacylamino, acyloxy, alkylyllphonyloxy, arylsulphonyloxy, heterocycloalkylamino, alkylsulphonyl, arylsulphonyl, carboalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, nitro, sulfate and phosphate;

and each p is from 0-5.

- 133. (New) A method for the treatment of cancer as in claim 119, wherein the compound has a potency of cytotoxicity of IC₅₀ \leq 10 μ M against MM96 melanoma cells.
- 134. (New) A method for the treatment of cancer as in claim 133, wherein the compound has a Selectivity Index of ≥ 1.5 .
- 135. (New) A method for the treatment of cancer as in claim 134, wherein the compound has a potency of $IC_{50} \le 1$ μM against the MM96 melanoma cells and a Selectivity Index of ≥ 3 .
- 136. (New) A method for the treatment of cancer as in claim 135, wherein the compound has a potency of $IC_{50} \le 0.5 \mu M$ against the MM96 melanoma cells and a Selectivity Index of ≥ 4 .
- 137. (New) A method for the treatment of cancer as in claim 119, wherein the animal is a human.

National Stage of PCT/AU2004/001667 Attorney Docket No. P1119/20002 Preliminary Amendment Dated: May 26, 2006

- 138. (New) A pharmaceutical composition containing one or more of the compounds of claim 84 and a pharmaceutically acceptable, carrier, diluent or excipient.
- 139. (New) The use of any one or more of the compounds of claim 84 for the preparation of a medicament for the treatment of cancer.